删除或更新信息,请邮件至freekaoyan#163.com(#换成@)
广东药科大学导师教师师资介绍简介-徐爱民
/2021-06-06
广东药科大学研究生导师简介
姓 名 徐爱民 性 别 男
出生年月
1967 年 9 月
籍贯 安徽
民 族 汉族 政治面貌 群众
最后学历 博士 最后学位 博士
技术职称
特聘教授
行政职务 无
工作单位
香港大学
amxu@hkucc.hku.hk
主要研究领域
肥胖、糖尿病和心血管疾病的分子机制以及脂肪和肝脏组织来源的新型代谢激素的代谢代
谢调控功能和机制。
主要工作经历
2013.6-现在 香港大学生物医药技术国家重点实验室主任
(2016.08-现在广东药科大学特聘教授,中西医结合学科珠江学者讲座教授)
2010.5-现在 香港大学内科学系及药理学系终身教授,香港大学抗体及免疫检测服务中心主任
2005.8-2010.4 香港大学内科学系副教授(终身教职)及助理教授
2002.8-2005.7 香港大学内科学系研究助理教授
2001.1-2002.8 奥克兰大学生物科学系研究员,新西兰 Protemix 生物技术公司资深研究科学家
1999.10-2000.12 奥克兰大学分子医学系博士后
第 1 页/共 5 页
主要教育经历
2000 新西兰奥克兰大学,获理学硕士及哲学博士学位
1989 安徽医科大学,获临床医学学士学位
代表性获奖、荣誉称号
2005-2006 香港大学杰出青年学者
2000 奥克兰大学最佳博士论文
代表性社会、学会及学术兼职
1. Biochemical Journal 副主席(2013-现在)
2. Adipocytes 杂志编委会成员(2011-现在)
3. 德国德累斯顿大学内科学系客座教授(2011.10-现在)
4. Cardiovascular Drugs and Therapy 编委会成员(2010-现在)
5. 中南大学湘雅医学院客座教授(2008.12-现在)
6. Journal of Diabetes 编委会成员(2008-现在)
7. Journal of Obesity 编辑(2008-现在)
8. Clinical Science 杂志编辑(2008-现在)
9. PLOS ONE 杂志编辑(2007-现在)
10. 中国科学院广州生物医学与健康研究院客座教授(2006.9-现在)
代表性 10 项科研项目
1. RGC Collaborative Research Fund,C7055-14G,A Multi-disciplinary Approach to Investigate
Vascular Dysfunction in Obesity and Diabetes: From Molecular Mechanism to Therapeutic
Intervention,PI
第 2 页/共 5 页
2. Health and Medical Research Fund,2132836,FGF21 resistance as a potential mediator of
systemic insulin resistance and type 2 diabetes,PI
3. NSFC/RGC Joint Research Scheme , N_HKU726/14 , Fatty acid binding protein-4 as a
mediator of autoimmune diabetes: from molecular mechanism to clinical significance,PI
4. Germany/HK Joint Research Scheme,G_HK708/13,Adipocyte fatty acid binding protein as a
mediator of obesity-related medical complications,PI
5. RGC collaborative research fund , HKU4/CRF/10 , A multiple disciplinary approach to
investigate vascular dysfunction in obesity and diabetes: From molecular mechanism to
therapeutic intervention,PI
6. France ANR/RGC research Scheme,A-HKU-705/13,The gut microbiota-adipose tissue axis in the
pathogenesis of obesity and its related metabolic disorders: molecular mechanism and clinical
implications,PI
7. General Research Fund,HKU17124714,Interplay between Adiponectin and Alternatively- activated
Macrophages in Cold-induced Remodeling and Adaptive Thermogenesis of White Adipose Tissues,PI
8. General Research Fund ,HKU783413M , Fibroblast growth factor 21 maintains glucose
homeostasis during fasting by mediating the crosstalk between liver and brain,PI
9. General Research Fund,HKU 782612M,The adaptor protein APPL1 as a physiological
regulator of insulin secretion in pancreatic cells,PI
10. General Research Fund,HKU 784111M,The Liver-derived Hormone FGF21 as a Novel Regulator of
Vascular Function: Molecular Basis and Physiological Implications,PI
发表代表性 10 篇论文、专著或教材
1. Liu, Y., Y. Wang, Y. Ni, C. K. Y. Cheung, K. S. L. Lam, Y. Wang, Z. Xia, D. Ye, J. Guo, M.
A. Tse, G. Panagiotou and Aimin Xu. Gut Microbiome Fermentation Determines the Efficacy of Exercise
for Diabetes Prevention. Cell Metabolism, 2020, 31(1): 77-91.e75.
2. Pan, Y., X. Hui, R. L. C. Hoo, D. Ye, C. Y. C. Chan, T. Feng, Y. Wang, K. S. L. Lam and
Aimin Xu. Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to
promote obesity-induced adipose inflammation. The Journal of Clinical Investigation, 2019, 129(2):
834-849.
第 3 页/共 5 页
3. Huang, Z., L. Zhong, J. T. H. Lee, J. Zhang, D. Wu, L. Geng, Y. Wang, C. M. Wong and Aimin
Xu. The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling
Sympathetic Nervous System to Type 2 Immunity. Cell Metabolism, 2017, 26(3): 493-
508.e494.
4. Li, H., G. Wu, Q. Fang, M. Zhang, X. Hui, B. Sheng, L. Wu, Y. Bao, P. Li, Aimin Xu and W.
Jia. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion
of subcutaneous fat. Nature Communications, 2018, 9(1): 272.
5. Liao, B., L. Geng, F. Zhang, L. Shu, L. Wei, P. K. K. Yeung, K. S. L. Lam, S. K. Chung, J.
Chang, P. M. Vanhoutte, Aimin Xu, K. Wang and R. L. C. Hoo. Adipocyte fatty acid-binding protein
exacerbates cerebral ischaemia injury by disrupting the blood-brain barrier. European Heart
Journal. 2020, DOI: 10.1093/eurheartj/ehaa207
6. Hui X, Gu P, Zhang J, Nie T, Pan Y, Wu D, Feng T, Zhong C, Wang Y, Lam KSL, Xu A*.
Adiponectin Enhances Cold-Induced Browning of Subcutaneous Adipose Tissue via
Promoting M2 Macrophage Proliferation. Cell Metab. 2015 Aug 4; 22(2):279-290.
7. Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y, Jin L, Lian Q, Huang Y, Ding H, Triggle C, Wang
K, Li X*, Xu A*. Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic
Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice. Circulation. 2015
Mar 26;131(21):1861-71.
8. Yau SY, Li A, Hoo RL, Ching YP, Christie BR, Lee TM, Xu A*, So KF*. Physical exercise-
induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone
adiponectin. Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15810-5.
9. Wang Y, Xiao Y, Zhong L, Ye D, Zhang J, Tu Y, Bornstein SR, Zhou Z*, Lam KS*, Xu A*.
Increased Neutrophil Elastase and Proteinase 3 and Augmented NETosis Are Closely
Associated with β-cell Autoimmunity in Patients with Type 1 Diabetes. Diabetes. 2014
Dec;63(12):4239-48.
第 4 页/共 5 页
10. Cheng KKY*, Zhu W, Chen B, Wang Y, Wu D, Sweeney G, Wang B, Lam KSL, Xu A*, The
adaptor protein APPL2 inhibits insulin-stimulated glucose uptake by interacting with TBC1D1
in skeletal muscle. Diabetes, 2014 Nov;63(11):3748-58.
发表代表性 10 授权专利或成果转化
1. Lipocalin-2 抗体作为治疗方法,美国专利号:8481032B2
2. Lipocalin-2 作为心脏和中风风险的预后和诊断标志物,美国专利号:8030097B2
3. 胰岛素和胰岛素拮抗剂的磷蛋白靶标,美国专利号:6884575
4. 脂联素及其用途,美国专利号:7365170
5. Lipocalin-2 作为诊断标志物和治疗靶标,美国专利号:7645616 6. FALP 蛋白,国际申请号:PCT/NZ03/00039,美国 20050074756
7. 具有抗肥胖活性和其他相关用途的肽,美国专利申请号:20070275872
8. 使用血管生成素样蛋白 4 降低血糖并改善葡萄糖耐量的方法,美国专利申请号:
20080095782,美国专利申请 20090274709
第 5 页/共 5 页